
Opinion|Videos|December 10, 2024
Insights on Managing Cough Symptoms in Patients With IPF
Author(s)Steven D. Nathan, MD
Key Takeaways
- Current IPF cough treatments are often inadequate, highlighting the need for improved therapeutic strategies and a deeper understanding of underlying mechanisms.
- The study identifies potential pathways for novel interventions, which could significantly enhance patient quality of life by targeting specific mechanisms.
Steven Nathan, MD, discusses how the findings from the study on oral nalbuphine extended release suggest that this treatment may offer an effective option for managing IPF-related cough, providing significant relief in terms of both frequency and severity, which could shift current management strategies by introducing a more targeted, pharmacologic approach to addressing one of the most challenging symptoms of IPF.
Advertisement
Episodes in this series

- What are your key takeaways from this study, and how might these findings impact the way IPF cough symptoms are currently managed?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
Value-Based Care Interventions and Management of CKD Progression
4
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
5